Abstract:An imbalance between bone resorption and bone formation underlies the devastating osteolytic lesions and subsequent fractures seen in more than 90% of multiple myeloma (MM) patients. Currently, Wnt‐targeted therapeutic agents that prevent soluble antagonists of the Wnt signaling pathway, sclerostin (SOST) and dickkopf‐1 (DKK1), have been shown to prevent bone loss and improve bone strength in pre‐clinical models of MM. In this study, we show increasing Wnt signaling via a novel anti‐LRP6 antibody, which potentiates Wnt1‐class ligand signaling through binding the Wnt receptor LRP6, prevented the development of myeloma‐induced bone loss primarily through preventing bone resorption. When combined with an agent targeting the soluble Wnt antagonist DKK1, we showed more robust improvements in bone structure than anti‐LRP6 treatment alone. MicroCT analysis demonstrated substantial increases in trabecular bone volume in naïve mice given the anti‐LRP6/DKK1 combination treatment strategy compared to control agents. Mice injected with 5TGM1eGFP murine myeloma cells had significant reductions in trabecular bone volume compared to naïve controls. The anti‐LRP6/DKK1 combination strategy significantly improved bone volume in 5TGM1‐bearing mice by 111%, which was also superior to anti‐LRP6 single treatment; with similar bone structural changes observed within L4 lumbar vertebrae. Consequently, this combination strategy significantly improved resistance to fracture in lumbar vertebrae in 5TGM1‐bearing mice compared to their controls, providing greater protection against fracture compared to anti‐LRP6 antibody alone. Interestingly, these improvements in bone volume were primarily due to reduced bone resorption, with significant reductions in osteoclast numbers and osteoclast surface per bone surface demonstrated in 5TGM1‐bearing mice treated with the anti‐LRP6/DKK1 combination strategy. Importantly, Wnt stimulation with either single or combined Wnt‐targeted agents did not exacerbate tumor activity. This work provides a novel approach of targeting both membrane‐bound and soluble Wnt pathway components to provide superior skeletal outcomes in patients with multiple myeloma and other bone destructive cancers. This article is protected by copyright. All rights reserved.

RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model

Isoalantolactone Inhibits RANKL-induced Osteoclast Formation Via Multiple Signaling Pathways

RANKL Inhibition is an Effective Adjuvant for Docetaxel in a Prostate Cancer Bone Metastases Model

RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies

A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment

Soluble Receptor Activator of Nuclear Factor Kappa B Fc Diminishes Prostate Cancer Progression in Bone

The RANK/RANKL/OPG system and tumor bone metastasis: Potential mechanisms and therapeutic strategies

Tectorigenin inhibits RANKL-induced osteoclastogenesis via suppression of NF-κB signalling and decreases bone loss in ovariectomized C57BL/6.

Study on anti-bone metastasis of breast cancer by a fusion protein of RANKL-Fc

Targeting the RANKL/RANK/OPG Axis for Cancer Therapy

RSPO2 and RANKL signal through LGR4 to regulate osteoclastic premetastatic niche formation and bone metastasis

Rictor ablation in BMSCs inhibits bone metastasis of TM40D cells by attenuating osteolytic destruction and CAF formation

RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives

Targeting RANK/RANKL in the treatment of solid tumours and myeloma

Roles of the RANKL–RANK Axis in Immunity—Implications for Pathogenesis and Treatment of Bone Metastasis

Breast cancer cells promote osteoclast differentiation in an MRTF-dependent paracrine manner

Overexpression of a functional calcium-sensing receptor dramatically increases osteolytic potential of MDA-MB-231 cells in a mouse model of bone metastasis through epiregulin-mediated osteoprotegerin downregulation

P2RX7 inhibition reduces breast cancer induced osteolytic lesions - implications for bone metastasis

Overexpression of Lrp5 enhanced the anti-breast cancer effects of osteocytes in bone

Multi‐targeting DKK1 and LRP6 Prevents Bone Loss and Improves Fracture Resistance in Multiple Myeloma